ea0037gp.22.04 | Pituitary–Therapy of Cushing's disease | ECE2015
Petersenn Stephan
, Salgado Luiz R
, Schopohl Jochen
, Portocarrero-Ortiz Lesly
, Arnaldi Giorgio
, Lacroix Andre
, Ravichandran Shoba
, Kandra Albert
, Bagulho Teresa
, Biller Beverly MK
Background: In a large 12-month Phase III study, pasireotide led to rapid and sustained decreases in UFC and provided clinical benefit in patients with Cushings disease. Here, we report data following an open-label, open-ended extension.Methods: 162 patients with persistent/recurrent or de novo Cushings disease were randomized in the core study. 58 patients with mean UFC≤ULN or clinical benefit at month 12 entered the extension...